One of Australia’s newest biotech investment funds is set to triple investments on the back of its success and strong investor demand. The three-year old Merchant Biotech Fund (MBF) invested in several high growth ASX-listed and private life sciences companies and finished the past financial year up more than 70%. It is up 10% for the current financial year, Portfolio Manager Reece O'Connell told BioWorld.

Apimeds Pharmaceuticals US Inc., a subsidiary of Seoul, South Korea-based Inscobee Inc., is “counting down” to an official IPO on the New York Stock Exchange with its S-1 filing showing a targeted offering of $11.5 million.

Biopharmas raising money in public or private financings, including: Aktis, Clene, Mesoblast. Poxel, Sumitomo.

Med-tech firms raising money in public or private financings, including: Elekta, Skincure Oncology.

Biopharmas in Asia-Pacific raising money in public or private financings: Apimeds, Immutep, Inscobee, Longbio.

Apimeds Pharmaceuticals US Inc., a subsidiary of Seoul, South Korea-based Inscobee Inc., is “counting down” to an official IPO on the New York Stock Exchange with its S-1 filing showing a targeted offering of $11.5 million.

Biopharmas raising money in public or private financings, including: Cue, Eyenovia, Nurexone, Theriva.

Med-tech firms raising money in public or private financings, including: Brainsway, Mindpeak, Perimeter Medical Imaging.